RT Journal Article
SR Electronic
T1 Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: Study Protocol for a Pragmatic Randomized Controlled Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.01.20087999
DO 10.1101/2020.05.01.20087999
A1 Lother, Sylvain A
A1 Abassi, Mahsa
A1 Agostinis, Alyssa
A1 Bangdiwala, Ananta S
A1 Cheng, Matthew P
A1 Drobot, Glen
A1 Engen, Nicole
A1 Hullsiek, Kathy H
A1 Kelly, Lauren E
A1 Lee, Todd C
A1 Lofgren, Sarah M
A1 MacKenzie, Lauren J
A1 Marten, Nicole
A1 McDonald, Emily G
A1 Okafor, Elizabeth C
A1 Pastick, Katelyn A
A1 Pullen, Matthew F
A1 Rajasingham, Radha
A1 Schwartz, Ilan
A1 Skipper, Caleb P
A1 Turgeon, Alexis F
A1 Zarychanski, Ryan
A1 Boulware, David R
YR 2020
UL http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087999.abstract
AB Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 causing the coronavirus disease 2019 (COVID-19) pandemic. Currently, there are a lack of evidence-based therapies to prevent COVID-19 following exposure, or to prevent worsening of symptoms following confirmed infection. We describe the design of a clinical trial of hydroxychloroquine for post-exposure prophylaxis and pre-emptive therapy for COVID-19.Methods We will conduct two nested multicenter international double-blind randomized placebo-controlled clinical trials of hydroxychloroquine for: 1) post-exposure prophylaxis (PEP) of asymptomatic household contacts or healthcare workers exposed to COVID-19 within the past four days, and 2) pre-emptive therapy (PET) for symptomatic outpatients with COVID-19 with a total symptom duration of less than 4 days. We will recruit 1500 patients for each the PEP and PET trials. Participants will be randomized 1:1 to receive 5 days of hydroxychloroquine or placebo. The primary PEP trial outcome will be the incidence of symptomatic COVID-19 disease. The primary PET trial outcome will be an ordinal scale of disease severity (not hospitalized; hospitalized without intensive care, hospitalization with intensive care, or death). Participant screening, informed consent, and follow up will be exclusively internet-based with appropriate regulatory and research ethics board approvals in Canada and the United States.Discussion These complementary randomized control trials are innovatively designed and adequately powered to rapidly answer urgent questions regarding the effectiveness of hydroxychloroquine to reduce transmission and disease severity of COVID-19 during a pandemic. In-person participant follow-up will not be conducted in order to facilitate social distancing strategies and reduce risks of exposure to study personnel. Innovative trial approaches are needed to urgently assess therapeutic options to mitigate the global impact of this pandemic.Trials Registration clinicaltrials.gov (NCT04308668); 16 March 2020.Competing Interest StatementDrs. Emily G. McDonald and Todd C. Lee receive salary support from the Fonds de recherche du Québec – Santé. Dr. Cheng is a member of the scientific advisory board of GEn1E Lifesciences. Ryan Zarychanski is the recipient of the Lyonel G Israsels Professorship in Hematology at the University of Manitoba. Additional authors declare no conflicts of interest.Clinical TrialNCT 04308668Funding StatementU.S. Funding by Jan and David Baszucki, Alliance of Minnesota Chinese Organizations, Minnesota Chinese Chamber of Commerce, and University of Minnesota. Canadian funding by the Manitoba Medical Service Foundation. The funders will not contribute to the design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication. Purolator Canada provided in-kind courier support for the participating Canadian sites.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be provided when the full trial results are published